Proton therapy

Open Letter to ViewRay Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global Companies

Retrieved on: 
Friday, October 13, 2023
Software, Research, Radiology, Oncology, Medical Devices, Technology, Hospitals, Health Technology, Science, Biotechnology, FDA, Health, Proton, Carbon, TBG, Cell, Radionuclide, Cyclotron, Blood, Proton therapy, Maintenance, IMRT, Brachytherapy

TeamBest Global Companies (TBG) have been in business since 1951—over 70 years—with many innovations in Brachytherapy, Teletherapy, IMRT treatment planning software, Heavy Ion 400 MeV ion, Rapid Cycling Medical Synchrotron Proton-to-Carbon, a range of cyclotrons from 1 MeV to 200 MeV for research, Radioisotope Production, Proton Therapy, Theranostics/Targeted Systemic Radiation Therapy, Blood, Animal Cell and Research Irradiators, etc.

Key Points: 
  • TeamBest Global Companies (TBG) have been in business since 1951—over 70 years—with many innovations in Brachytherapy, Teletherapy, IMRT treatment planning software, Heavy Ion 400 MeV ion, Rapid Cycling Medical Synchrotron Proton-to-Carbon, a range of cyclotrons from 1 MeV to 200 MeV for research, Radioisotope Production, Proton Therapy, Theranostics/Targeted Systemic Radiation Therapy, Blood, Animal Cell and Research Irradiators, etc.
  • I am saddened by ViewRay’s recent announcement that their operations will soon cease and that after October, their customers may not be able to receive support for service, maintenance, quality and regulatory issues, upgrades, etc.
  • TBG Companies have 1000s of Teletherapy units—Cobalt 60 Gamma Beam with IMRT capabilities on some, and 1000 plus X Ray, Cesium 137 Blood, Animal, Cell and Research Irradiators, among other products.

Prominent U.S. hospital expands RayStation installation for proton treatment planning

Retrieved on: 
Friday, October 13, 2023
LET, Doctor of Philosophy, RaySearch Laboratories, Mass, Proton, Research, Software, Proton therapy, FLASH, Physics, Radiation therapy, Massachusetts General Hospital, Pharmaceutical industry, Medical imaging

STOCKHOLM, Oct. 13, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that the Mass General Cancer Center plans to expand its use of RayStation®* to proton treatment planning.

Key Points: 
  • STOCKHOLM, Oct. 13, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that the Mass General Cancer Center plans to expand its use of RayStation®* to proton treatment planning.
  • RayStation is a flexible, innovative cancer treatment planning system developed by RaySearch.
  • The software offers features for proton therapy planning such as multi-criteria optimization, LET evaluation, and optimization, as well as modalities under development such as proton arcs and FLASH.
  • The Mass General Cancer Center, which was the first in the world to offer proton therapy, is in the process of transitioning its proton treatment planning system to RayStation.

Kantor & Kantor, LLP Promotes Timothy Rozelle to Partner

Retrieved on: 
Friday, October 13, 2023
Proton, Diagnosis, LLP, Kantor, California Department, Insurance, University, ABA, California Department of Insurance, Cancer, Long-term care, Proton therapy, Lawyer, Coalition, PBT, Patient, Spectrum, Health insurance, Nursing

NORTHRIDGE, Calif., Oct. 13, 2023 /PRNewswire/ -- Kantor & Kantor, LLP, continues to build an exceptional team of superbly talented and diverse lawyers across their practice areas to carry the firm forward.

Key Points: 
  • NORTHRIDGE, Calif., Oct. 13, 2023 /PRNewswire/ -- Kantor & Kantor, LLP, continues to build an exceptional team of superbly talented and diverse lawyers across their practice areas to carry the firm forward.
  • Lisa Kantor said, "I am thrilled that Tim Rozelle has been promoted to partner at Kantor & Kantor.
  • "More than in any other professional environment I have been in, here at Kantor & Kantor I feel most like I can be myself.
  • You can reach Mr. Rozelle via email at [email protected] or call our Northridge, California main office at (818) 886-2525.

Hitachi's Proton Therapy System Now in Use at National Cancer Centre Singapore

Retrieved on: 
Wednesday, October 4, 2023
Proton, Education, Proton therapy, Neoplasm, Respiration, Cancer, Light, Quality of life, Rehabilitation, Research, Carbon, Noetics, Motion, Hospital, SingHealth, Patient, NCCS, Medical imaging

TOKYO, Oct 4, 2023 - (JCN Newswire) - Hitachi, Ltd. (TSE:6501, "Hitachi") and Hitachi Asia Ltd. announced today that it has delivered to National Cancer Centre Singapore ("NCCS") a proton therapy system, with which NCCS has completed the first patient treatment as of 11 August 2023.

Key Points: 
  • TOKYO, Oct 4, 2023 - (JCN Newswire) - Hitachi, Ltd. (TSE:6501, "Hitachi") and Hitachi Asia Ltd. announced today that it has delivered to National Cancer Centre Singapore ("NCCS") a proton therapy system, with which NCCS has completed the first patient treatment as of 11 August 2023.
  • This marks Hitachi's first proton therapy system to start treatment in Southeast Asia.
  • NCCS is a leading national and regional tertiary cancer centre with specialists who are experts in treating cancer.
  • Hitachi provides products and services of particle therapy systems with higher performance and added value, which can be found in leading hospitals around the world, ranging from proton therapy system, heavy ion therapy system to hybrid system combined with the capabilities of proton and carbon therapy.

P-Cure Collaborates with RaySearch on P-Cure's Gantry-Less Seated Proton System Designed to Fit within Linac Vaults

Retrieved on: 
Monday, October 2, 2023
Proton, Partnership, Proton therapy, RaySearch Laboratories, Head, Neck, CNS, Hadassah Medical Center, FDA, Environment, Automation, Medical imaging, Pharmaceutical industry

The partnership is an organic continuation of the existing relationship between the companies that already resulted in integration of RayStation, the RaySearch treatment planning system, in a study conducted at the P-Cure Clinical Development Center operated clinically by Hadassah -- the only available proton facility in the Middle East.

Key Points: 
  • The new P-Cure and RaySearch collaboration will enable users of the P-Cure Proton Therapy System to use RayStation and RayCare in a seamlessly integrated environment.
  • SHILAT, Israel, Oct. 2, 2023 /PRNewswire-PRWeb/ -- The new P-Cure and RaySearch collaboration will enable users of the P-Cure Proton Therapy System to use RayStation and RayCare in a seamlessly integrated environment.
  • The P-Cure Proton Therapy System is a compact gantry-less proton therapy solution that has been recently cleared by the FDA.
  • P-Cure is a pioneer in the development of upright radiation therapy and the ability to provide a proton system in a regular Linac room has great potential to expand proton therapy."

Mevion and RaySearch: A Synergy of Innovation Transforming Proton Therapy

Retrieved on: 
Monday, October 2, 2023
Technology, Research, Medical Devices, Health Technology, Software, Radiology, Health, Science, Oncology, Proton, Partnership, Proton therapy, RaySearch Laboratories, Radiation, FLASH, Algorithm, Varian Medical Systems, Neoplasm, Medical imaging

The collaboration leverages both companies’ domain expertise in the advancement of innovative solutions for HYPERSCAN IMPT, adaptive therapy, proton arc therapy, and FLASH proton therapy.

Key Points: 
  • The collaboration leverages both companies’ domain expertise in the advancement of innovative solutions for HYPERSCAN IMPT, adaptive therapy, proton arc therapy, and FLASH proton therapy.
  • Mevion has integrated in-room diagnostic CT imaging on the MEVION S250i and MEVION S250-FIT platforms to optimize the use of adaptive therapy.
  • Proton arc therapy: Arc therapy is an emerging proton therapy treatment delivery technique that optimizes rotational techniques of a gantry or upright patient positioner to conform and precisely target a tumor from multiple angles.
  • We are committed to breaking down technological and clinical access barriers to superior proton therapy technology.”
    Johan Löf, Founder and CEO of RaySearch, states, “RaySearch’s expertise in oncology software and Mevion Medical Systems’ latest technological advancements will continue to bring innovation in the proton therapy field and we look forward to working together with Mevion to further advance proton cancer treatments.”
    *The MEVION S250-FIT Proton Therapy System™, FLASH therapy, online adaptive therapy, and Arc therapy are not yet available for clinical use.

Paul Scherrer Institute selects RayStation

Retrieved on: 
Monday, October 2, 2023
PSI, RaySearch Laboratories, Paul Scherrer Institute, Indiana University Health Proton Therapy Center, Cancer, Partnership, Research, Proton therapy, Medical imaging

STOCKHOLM, Oct. 2, 2023 /PRNewswire/ -- Renowned worldwide for its treatment of cancers with proton therapy, PSI has selected RayStation as the treatment planning system for its clinical operations. PSI is equipped with three gantries and a fixed horizontal beam line room for ocular treatments. Two of the gantries, of which one is in-house developed, operate clinically while the third is dedicated to research.

Key Points: 
  • STOCKHOLM, Oct. 2, 2023 /PRNewswire/ -- Renowned worldwide for its treatment of cancers with proton therapy, PSI has selected RayStation as the treatment planning system for its clinical operations.
  • Two of the gantries, of which one is in-house developed, operate clinically while the third is dedicated to research.
  • Alongside the procurement of RayStation, RaySearch and PSI have the intent of engaging in a collaborative research initiative.
  • Damien C. Weber, Chairman of the proton Therapy Center, Paul Scherrer Institute, says: "By combining proton therapy with advanced treatment planning system as proposed by RaySearch, we can push the boundaries of optimal cancer care.

RaySearch deepens collaboration with P-Cure

Retrieved on: 
Monday, October 2, 2023
Neck, RaySearch Laboratories, Hadassah Medical Center, Partnership, FDA, Head, Environment, Automation, Proton therapy, CNS, Pharmaceutical industry, Medical imaging

STOCKHOLM, Oct. 1, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce its expanded collaboration with P-Cure, aiming at enhancing the workflow efficiency of P-Cure's proton therapy system through integration with RaySearch's systems RayStation®* and RayCare®*.

Key Points: 
  • STOCKHOLM, Oct. 1, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce its expanded collaboration with P-Cure, aiming at enhancing the workflow efficiency of P-Cure's proton therapy system through integration with RaySearch's systems RayStation®* and RayCare®*.
  • The expanded collaboration will enable users of the P-Cure proton therapy system to use RayStation and RayCare in a seamlessly integrated environment.
  • The P-Cure system is a gantry-less seated proton system, designed to fit within linac vaults, that has recently been cleared by the FDA.
  • Johan Löf, founder and CEO, RaySearch, says: "We are proud to work with a company that is ushering in a new era of proton therapy.

Mevion Launches “Mevion Capital” to Provide Customized Proton Therapy Funding Solutions for Healthcare Communities in US and Canada

Retrieved on: 
Sunday, October 1, 2023
Radiology, General Health, Health, Oncology, Varian Medical Systems, Cancer, Hospital, Radiation, Patient, Proton therapy, Medical imaging

In a healthcare landscape with growing budgetary constraints and reduced access to funding, Mevion Capital offers tailored financial solutions for the proton therapy industry.

Key Points: 
  • In a healthcare landscape with growing budgetary constraints and reduced access to funding, Mevion Capital offers tailored financial solutions for the proton therapy industry.
  • It aims to empower healthcare communities to upgrade existing radiation oncology services or establish new cancer centers with Mevion’s cutting-edge compact proton therapy technology.
  • Mevion Capital, in conjunction with Mevion's innovative compact proton therapy technology and end-to-end comprehensive solutions, is spearheading a paradigm shift.
  • We commit to reducing the financial barriers the healthcare communities may face to enable them to incorporate Mevion's compact proton therapy technology."

RaySearch receives order for RayStation and RayCare in Italy

Retrieved on: 
Friday, September 29, 2023
Workflow, Proton therapy, RaySearch Laboratories, Patient, IBA, Medical imaging

The order includes implementation of both RayStation and RayCare at C.R.O.

Key Points: 
  • The order includes implementation of both RayStation and RayCare at C.R.O.
  • Aviano.
  • The combination of RayStation and RayCare provides an integrated and unified solution throughout the complete workflow, when combined with an IBA proton therapy machine.
  • RaySearch partnered with IBA for the public tender and the center has now decided to select RayStation and RayCare.